Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

A Comprehensive Overview of the Bipolar Spectrum

Source: Advancing Care in Bipolar Depression
Listen as 2 experts in psychiatry provide an overview of the bipolar spectrum, including identifying bipolar depression with mixed presentations and various treatment strategies.
Charles DeBattista, MD
Greg W. Mattingly, MD
Released: July 7, 2022

In this episode, Drs Greg W. Mattingly and Charles DeBattista have a conversation about the history and features of the bipolar spectrum. Because patients can present in mixed vignettes, diagnosis of bipolar depression can be challenging. The experts offer insight on when to hold a suspicion for bipolar depression, as well as common presentations they have seen over their years in clinical practice. The conversation then progresses to potential “triggers” of bipolar depression and culminates with a discussion of the current treatment paradigm for patients with bipolar depression: first- or second-generation antipsychotics.

Information on this Educational Activity

Faculty

Greg W. Mattingly, MD

Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
Midwest Research Group
St. Louis, Missouri

Greg W. Mattingly, MD: speaker: AbbVie, Alkermes, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris Pharma; consultant: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neos, Neurocrine, Noven, Otsuka, Redax, Rhodes, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, Teva, Tris Pharma; researcher: AbbVie, Acadia, Akili, Alkermes, Axsome, Boehringer, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.
Charles DeBattista, MD

Chief, Depression Research Clinic
Director, Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California

Charles DeBattista, DMH, MD: researcher: Biolite, Compass, Janssen, Myriad, Neurocentria, Relmada, Sage; consultant: AbbVie, Corcept.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Intra-Cellular Therapies, Inc.

Related Content

Slides from a presentation that educates clinicians on new and emerging treatments for treating neuropsychiatric symptoms in Alzheimer’s disease dementia.

Marwan Sabbagh, MD, FAAN Released: September 19, 2022

Access this medications glossary for a list of common psychiatric medications.

Released: September 6, 2022

Experts in psychiatry discuss the patient symptoms and clues that can help to accurately diagnose bipolar depression, from Clinical Care Options (CCO)

Vladimir Maletic, MD Greg W. Mattingly, MD Released: September 2, 2022

Slides from a presentation that educates clinicians on managing major depression.

Manish Jha, MD Vladimir Maletic, MD Greg W. Mattingly, MD Released: August 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings